Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

DSGN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Design Therapeutics, Inc.NASDAQ: DSGN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$17.48M, compared with -$17.56M a year earlier. Trailing-twelve-month EBITDA was -$69.09M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -41.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.48M-10.3% QoQ
Last fiscal yearDec 2025
-$69.17M-41.2% YoY
LTMMar 2026
-$69.09M-24.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.4%+100.0%+99.6 pp
1 year-41.2%+100.0%+141.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(69.17M) USD
Year-over-year change
-41.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How DSGN compares with its peers on the latest reported figures

  • DSGN's LTM Mar 2026 EBITDA of -$69.09M is the 3rd highest of the 11 companies compared; the peer median is -$164.89M.
  • Its year-over-year change of -24.3% is the 4th highest of 11, against a peer median of -71.5%.
DSGN Competitors Peer median
EBITDA for DSGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTCTPTC Therapeutics, Inc.LTM Jun 2026$173.52M -79.4%—17.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$124.95M +217.3%—5.7%
DSGNDesign Therapeutics, Inc.LTM Mar 2026-$69.09M -24.3%——
FULCFulcrum Therapeutics, Inc.LTM Mar 2026-$74.74M -18129.5%——
PEPGPepGen Inc.LTM Mar 2026-$75.99M +22.0%——
STOKStoke Therapeutics, Inc.LTM Mar 2026-$164.11M -405.9%—511.5%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$165.68M -74.6%——
WVEWave Life Sciences Ltd.LTM Mar 2026-$174.59M -68.4%—243.2%
SLDBSolid Biosciences Inc.LTM Mar 2026-$190.1M -38.9%——
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M -208.3%—49.3%
DYNDyne Therapeutics, Inc.LTM Jun 2026-$495.35M -20.6%——
Peer median (excluding DSGN) -$164.89M-71.5%—49.3%

Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0466K537K596K622K
Gross Profit0(466K)(537K)(596K)(622K)
Gross Margin—————
Research & Development24.78M48.61M57.06M44.35M59.13M
Selling, General & Admin11.05M18.98M21.13M18.03M20.34M
Operating Expenses35.83M67.13M77.65M61.79M78.85M
Depreciation & Amortization129K466K537K596K622K
EBITDA(35.4M)(62.84M)(66.33M)(48.99M)(69.17M)
EBITDA Margin—————
Operating Income(35.83M)(67.59M)(78.19M)(62.38M)(79.47M)
Operating Margin—————
Interest Income00012.8M9.68M
Interest Expense00000
Other Income / Expenses298K4.29M11.33M12.8M9.68M
Income Before Tax(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(35.53M)(63.31M)(66.86M)(49.59M)(69.79M)
Net Margin—————
EPS (Basic)(0.77)(1.14)(1.19)(0.88)(1.22)
EPS (Diluted)(0.77)(1.14)(1.19)(0.88)(1.22)
Weighted Avg Shares45.94M55.71M55.98M56.59M57.33M
Weighted Avg Shares (Diluted)45.94M55.71M55.98M56.59M57.33M

Design Therapeutics, Inc.

NASDAQ:DSGN

Intrinsic Alpha fair value

Locked

Current Price

$9.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.